Ankylosing Spondylitis and Mesenchymal Stromal/Stem Cell Therapy: A New Therapeutic Approach

Ankylosing Spondylitis and Mesenchymal Stromal/Stem Cell Therapy: A New Therapeutic Approach Publisher Pubmed

Abdolmohammadi K^{1, 2, 3} ; Pakdel FD² ; Aghaei H² ; Assadiasl S⁴ ; Fatahi Y⁵ ; Rouzbahani NH^{2, 3, 6} ; Rezaiemanesh A⁷ ; Soleimani M^{3, 8} ; Tayebi L⁹ ; Nicknam MH^{2, 4}

Show Affiliations

1. Department of Immunology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran
2. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
3. Department of Stem Cell Biology, Stem Cell Technology Research Center, Tehran, Iran
4. Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran
5. Department of Pharmaceutical Nanotechnology, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
6. Department of Immunology, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran
7. Department of Immunology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
8. Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
9. Marquette University School of Dentistry, Milwaukee, 53233, WI, United States

Source: Biomedicine and Pharmacotherapy Published:2019

Abstract

Ankylosing spondylitis (AS) is an inflammatory rheumatoid disease categorized within spondyloarthropathies (SpA) and manifested by chronic spinal arthritis. Several innate and adaptive immune cells and secreted-mediators have been indicated to play a role in AS pathogenesis. Considering the limitations of current therapeutic approaches (NSAIDs, glucocorticoids, DMARDs and biologic drugs), finding new treatments with fewer side effects and high therapeutic potentials are required in AS. Mesenchymal stem cells (MSCs) with considerable immunomodulatory and regenerative properties could be able to attenuate the inflammatory responses and help tissue repair by cell-to-cell contact and secretion of soluble factors. Moreover, MSCs do not express HLA-DR, which renders them a favorable therapeutic choice for transplantation in immune-mediated disorders. In the present review, we describe immunopathogenesis and current treatments restrictions of AS. Afterwards, immunomodulatory properties and applications of MSCs in immune-mediated disorders, as well as recent findings of clinical trials involving mesenchymal stem cell therapy (MSCT) in ankylosing spondylitis, will be discussed in detail. Additional studies are required to investigate several features of MSCT such as cell origin, dosage, administration route and, specifically, the most suitable stage of disease for ideal intervention. © 2018 Elsevier Masson SAS

Related Docs

View other Related Docs

1. Shining the Light on Clinical Application of Mesenchymal Stem Cell Therapy in Autoimmune Diseases, Stem Cell Research and Therapy (2022)

2. Immune Cells Involved in the Pathogenesis of Ankylosing Spondylitis, Biomedicine and Pharmacotherapy (2018)

3. An Overview to Ankylosing Spondylitis and Spondyloarthropathies, Ankylosing Spondylitis - Axial Spondyloarthritis: Cellular# Molecular and Environmental Factors (2021)

4. Innate Immune-Related Cells and Cytokines in Spondyloarthropathies, Ankylosing Spondylitis - Axial Spondyloarthritis: Cellular# Molecular and Environmental Factors (2021)

5. Multipotent Stem Cell and Current Application, Acta Medica Iranica (2017)

6. Evaluation of Pd-1 Gene Expression Profile and Methylation of the Regulatory Regions in Patients With Ankylosing Spondylitis, Iranian Journal of Immunology (2024)

7. Promoter Hypermethylation of Bcl11b Gene Correlates With Downregulation of Gene Transcription in Ankylosing Spondylitis Patients, Genes and Immunity (2017)

8. Role of Innate Immune System in the Pathogenesis of Ankylosing Spondylitis, Biomedicine and Pharmacotherapy (2018)

Experts (# of related papers)

View all Related Experts

Mahdi Mahmoudi (27)

Ahmad Reza Jamshidi (24)

Style	Citing Format
MLA	Abdolmohammadi K, et al.. "Ankylosing Spondylitis and Mesenchymal Stromal/Stem Cell Therapy: A New Therapeutic Approach." Biomedicine and Pharmacotherapy, vol. 109, no. , 2019, pp. 1196-1205.
APA	Abdolmohammadi K, Pakdel FD, Aghaei H, Assadiasl S, Fatahi Y, Rouzbahani NH, Rezaiemanesh A, Soleimani M, Tayebi L, Nicknam MH (2019). Ankylosing Spondylitis and Mesenchymal Stromal/Stem Cell Therapy: A New Therapeutic Approach. Biomedicine and Pharmacotherapy, 109(), 1196-1205.
Chicago	Abdolmohammadi K, Pakdel FD, Aghaei H, Assadiasl S, Fatahi Y, Rouzbahani NH, Rezaiemanesh A, Soleimani M, Tayebi L, Nicknam MH. "Ankylosing Spondylitis and Mesenchymal Stromal/Stem Cell Therapy: A New Therapeutic Approach." Biomedicine and Pharmacotherapy 109, no. (2019): 1196-1205.
Harvard	Abdolmohammadi K et al. (2019) 'Ankylosing Spondylitis and Mesenchymal Stromal/Stem Cell Therapy: A New Therapeutic Approach', Biomedicine and Pharmacotherapy, 109(), pp. 1196-1205.
Vancouver	Abdolmohammadi K, Pakdel FD, Aghaei H, Assadiasl S, Fatahi Y, Rouzbahani NH, et al.. Ankylosing Spondylitis and Mesenchymal Stromal/Stem Cell Therapy: A New Therapeutic Approach. Biomedicine and Pharmacotherapy. 2019;109():1196-1205.
BibTex	@article{ author = {Abdolmohammadi K and Pakdel FD and Aghaei H and Assadiasl S and Fatahi Y and Rouzbahani NH and Rezaiemanesh A and Soleimani M and Tayebi L and Nicknam MH}, title = {Ankylosing Spondylitis and Mesenchymal Stromal/Stem Cell Therapy: A New Therapeutic Approach}, journal = {Biomedicine and Pharmacotherapy}, volume = {109}, number = {}, pages = {1196-1205}, year = {2019} }
RIS	TY - JOUR AU - Abdolmohammadi K AU - Pakdel FD AU - Aghaei H AU - Assadiasl S AU - Fatahi Y AU - Rouzbahani NH AU - Rezaiemanesh A AU - Soleimani M AU - Tayebi L AU - Nicknam MH TI - Ankylosing Spondylitis and Mesenchymal Stromal/Stem Cell Therapy: A New Therapeutic Approach JO - Biomedicine and Pharmacotherapy VL - 109 IS - SP - 1196 EP - 1205 PY - 2019 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract